Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 8/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745672 | 0.96 | NFE2L2 (0.66) | PARP10PARP15PARP2NFE2L2TDP1 | |
| SCHEMBL2657957 | 0.94 | NFE2L2 (0.69) | PARP10PARP15PARP2NFE2L2HPGD | |
| SCHEMBL2565996 | 0.92 | PARP15 (0.59) | PARP10PARP15PARP2NFE2L2TDP1 | |
| Ethane SCHEMBL7214461 | 0.91 | NFE2L2 (0.65) | PARP10PARP15PARP2NFE2L2TDP1 | |
| SCHEMBL31434447 | 0.83 | PARP15 (0.56) | PARP10PARP15PARP2NFE2L2TDP1 | |
| SCHEMBL14320483 | 0.83 | PARP15 (0.47) | PARP10PARP15PARP2NFE2L2TDP1 | |
| SCHEMBL20969686 | 0.82 | PARP15 (0.55) | PARP10PARP15PARP2 | |
| SCHEMBL1674238 | 0.80 | CXCR1 (0.50) | — | |
| SCHEMBL29024848 | 0.80 | PARP15 (0.64) | PARP10PARP15PARP2TDP1 | |
| SCHEMBL3184573 | 0.80 | MAOA (0.53) | PARP10PARP15PARP2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057444-A1 | AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057444-A1 | AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-03-01 | — | — | US | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | PARP10 2174/4885PARP15 1905/4885PARP2 4188/4885 |
| US-20180057444-A1 | AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS | AHR, TYR, CYP1A1 | PARP10 341/4885PARP15 364/4885PARP2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.